Belite Bio (NASDAQ:BLTE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

Belite Bio (NASDAQ:BLTE) had its price objective lifted by equities researchers at Cantor Fitzgerald from $200.00 to $266.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price points to a potential upside of 49.61% from the stock’s current price.

BLTE has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and set a $185.00 price objective on shares of Belite Bio in a report on Wednesday, January 28th. Bank of America started coverage on shares of Belite Bio in a report on Monday, January 26th. They set a “buy” rating and a $195.00 price target for the company. Morgan Stanley started coverage on shares of Belite Bio in a research note on Tuesday, January 6th. They set an “overweight” rating and a $191.00 price objective on the stock. Maxim Group set a $200.00 price objective on shares of Belite Bio in a report on Tuesday, December 2nd. Finally, Mizuho set a $223.00 target price on Belite Bio in a report on Thursday, February 19th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $202.33.

Belite Bio Price Performance

NASDAQ:BLTE opened at $177.79 on Tuesday. The company has a fifty day moving average price of $169.39 and a 200 day moving average price of $123.68. The stock has a market cap of $6.67 billion, a P/E ratio of -77.30 and a beta of -1.46. Belite Bio has a one year low of $49.00 and a one year high of $200.00.

Belite Bio (NASDAQ:BLTE) last released its earnings results on Monday, March 2nd. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.18. As a group, equities research analysts anticipate that Belite Bio will post -1.17 EPS for the current year.

Institutional Investors Weigh In On Belite Bio

Several hedge funds and other institutional investors have recently made changes to their positions in BLTE. Caitong International Asset Management Co. Ltd raised its position in shares of Belite Bio by 54,800.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 549 shares of the company’s stock worth $88,000 after acquiring an additional 548 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in Belite Bio in the fourth quarter worth about $1,465,000. ADAR1 Capital Management LLC bought a new stake in Belite Bio during the 4th quarter worth about $6,373,000. Wellington Management Group LLP acquired a new position in Belite Bio during the 4th quarter valued at about $991,000. Finally, Squadron Capital Management LLC acquired a new position in Belite Bio during the 4th quarter valued at about $4,159,000. 0.53% of the stock is owned by institutional investors and hedge funds.

Belite Bio News Roundup

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Cantor Fitzgerald sharply raised its price target to $266 (from $200) and kept an overweight rating — a large read-through that likely attracted buying interest. Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
• Positive Sentiment: Company reported DRAGON trial success and said tinlarebant is advancing toward FDA review — a clinical milestone that materially de‑risks the lead program and supports the higher valuations. Belite Bio Advances Tinlarebant Toward FDA Review After DRAGON Success
• Positive Sentiment: Multiple brokerages raised targets/ratings (Morgan Stanley, H.C. Wainwright among them), signaling fresh institutional support and helping momentum. (See H.C. Wainwright StreetInsider coverage.) Belite Bio PT Raised to $200 at H.C. Wainwright
• Positive Sentiment: Q4 2025 results topped EPS expectations (less-negative EPS) and management reiterated a Q2 2026 NDA target — the earnings call helped validate the timeline investors care about. Belite Bio Inc (BLTE) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short-interest reports in early March appear anomalous/zero (NaN/0 values) and are unreliable as published — no clear evidence of a short squeeze or large persistent short position based on the available data.

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.